Healthcare entity
All 1 tracked stories fall under one category: regulation. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 5.8 in the same window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 5.8 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Healthcare story that mention ImmunityBio, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ImmunityBio. Shared-story counts are live from our verified record — not editorial picks.
FDA Warning Issued
The FDA flags the podcast statements as misleading and issues an Untitled Letter to ImmunityBio.
Podcast Appearance
Patrick Soon-Shiong discusses the drug's potential on a high-profile industry podcast.
Initial FDA Approval
Anktiva (N-803) receives FDA approval for BCG-unresponsive NMIBC.
The FDA has issued a formal warning to ImmunityBio and its founder, Patrick Soon-Shiong, regarding misleading public statements about the company's bladder cancer drug. The regulator cited claims made during a podcast that suggested broader efficacy than currently approved, raising concerns about off-label promotion.
ImmunityBio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
